⌘K
Change language Switch ThemeSign In
Narrow Mode
Decentralized vs. Centralized AI Drug Discovery
Decentralized vs. Centralized AI Drug Discovery
 ### 0xSammy@0xSammy
AI drug discovery is one of the most capital-intensive verticals in biotech
Recursion (NASDAQ: RXRX) alone has burned through $500M+ building proprietary compute infra
MetaNova (Bittensor SN68) flips the model entirely. Externalizes compute cost to TAO-incentivized miners competing across a 1.75B compound library; near-zero internal burn rate
Centralized players raised billions to do what decentralized miner competition might achieve at a fraction of the cost
Here’s a comparison table from our @KhalaResearch report (I’ll link below) breaking down the structural differences Show More
!Image 4: This Week in Startups
#### This Week in Startups
@twistartups · 17h ago x.com/i/article/2037…
4
22
98
17K
Mar 28, 2026, 5:49 AM View on X
12 Replies
13 Retweets
80 Likes
6,910 Views  0xSammy @0xSammy
One Sentence Summary
Compares the capital efficiency of decentralized AI drug discovery models against centralized incumbents like Recursion.
Summary
This tweet provides a comparative analysis of AI-driven drug discovery, contrasting the capital-intensive centralized approach (e.g., Recursion) with decentralized models (e.g., MetaNova/Bittensor). It highlights how decentralized compute incentives can significantly reduce internal burn rates compared to traditional biotech infrastructure, offering a structural perspective on cost-efficiency in the sector.
AI Score
82
Influence Score 23
Published At Today
Language
English
Tags
AI
Drug Discovery
Bittensor
Decentralized AI
Biotech HomeArticlesPodcastsVideosTweets